We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom (DXCM) Launches Latest CGM Sensor ONE in France
Read MoreHide Full Article
DexCom, Inc. (DXCM - Free Report) announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has been added under the country’s reimbursement packages that will provide an effective diabetes management system at affordable price.
The DexCom ONE CGM sensor can be used by all patients with type I and type II diabetes, aged two years and older, undergoing intensive insulin therapy — patients getting more than three insulin injection every day or using an external insulin pump.
Price Performance
Shares of DexCom have lost 14.9% year to date against the industry’s 5.8% growth. The S&P 500 Index has gained 17.1% in the same time frame.
Significance of the Launch
The use of DexCom ONE has been clinically proved to achieve lower HbA1C, reduce hyper and hypoglycaemia, and increase time in range. Meanwhile, the launch with reimbursement coverage will make the sensor accessible to majority of the eligible patient population. DexCom ONE will likely lead to confident treatment decisions in real time, without scanning, along with a real-time CGM with alerts.
The availability of DexCom ONE will also provide another option of a real-time CGM sensor for high-risk patients with type I diabetes and a new option to high-risk type II diabetes patients. Another real-time CGM sensor from the company’s portfolio, DexCom G6, is already available for type I patients in France. The G6 sensor is currently available through integrations with leading insulin delivery systems and digital health apps.
With the launch in France, the targeted patient population by DexCom ONE will increase by half a million, per the company’s statement. An improved accuracy and effectiveness pf DexCom compared with other glucose monitoring systems with reimbursement coverage may lead to accelerated adoption of DexCom ONE in France. This implies a significant growth opportunity for the company going ahead. The latest launch is likely to help the company to sustain its strong top and bottom-line growth trend, potentially leading to higher stock price.
Industry Prospects
Per a report by Knowledge Sourcing Intelligence, the wearable CGM market in France was valued at $90.6 million in 2021 and is likely to witness a CAGR of 17.4% (till 2028) to reach $278 million. Factors like high prevalence of type I and type II diabetes, launch of improved CGM devices, government awareness programs and reimbursement coverage for CGM devices are expected to drive the market.
Given the market potential, the launch of DexCom ONE is likely to provide a boost to DexCom’s already booming CGM business.
Notable Developments
In September, DexCom announced the availability of DexCom G6 CGM system that can connect with the Omnipod 5 Automated Insulin Delivery system in Germany.
In July, DexCom announced that its next-generation DexCom G7 CGM system received Health Canada’s approval for people with all types of diabetes, aged two years and above.
The same month, DexCom announced better-than-expected second-quarter results. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Moreover, expansion of coverage for CGM systems during the quarter supported growth, which is likely to continue for the rest of 2023. The availability of new sensors like G6 and G7 in new international markets is also boosting revenue growth.
Some better-ranked stocks in the broader medical space are Align Technology (ALGN - Free Report) , HealthEquity, Inc. (HQY - Free Report) and McKesson Corporation (MCK - Free Report) .
ALGN’s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company’s shares have risen 57.5% year to date compared with the industry’s 11.4% growth.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.1%.
The company’s shares have rallied 12% year to date against the industry’s 10.3% decline.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%.
The stock has rallied 12% year to date compared with the industry’s 11.4% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DexCom (DXCM) Launches Latest CGM Sensor ONE in France
DexCom, Inc. (DXCM - Free Report) announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has been added under the country’s reimbursement packages that will provide an effective diabetes management system at affordable price.
The DexCom ONE CGM sensor can be used by all patients with type I and type II diabetes, aged two years and older, undergoing intensive insulin therapy — patients getting more than three insulin injection every day or using an external insulin pump.
Price Performance
Shares of DexCom have lost 14.9% year to date against the industry’s 5.8% growth. The S&P 500 Index has gained 17.1% in the same time frame.
Significance of the Launch
The use of DexCom ONE has been clinically proved to achieve lower HbA1C, reduce hyper and hypoglycaemia, and increase time in range. Meanwhile, the launch with reimbursement coverage will make the sensor accessible to majority of the eligible patient population. DexCom ONE will likely lead to confident treatment decisions in real time, without scanning, along with a real-time CGM with alerts.
The availability of DexCom ONE will also provide another option of a real-time CGM sensor for high-risk patients with type I diabetes and a new option to high-risk type II diabetes patients. Another real-time CGM sensor from the company’s portfolio, DexCom G6, is already available for type I patients in France. The G6 sensor is currently available through integrations with leading insulin delivery systems and digital health apps.
With the launch in France, the targeted patient population by DexCom ONE will increase by half a million, per the company’s statement. An improved accuracy and effectiveness pf DexCom compared with other glucose monitoring systems with reimbursement coverage may lead to accelerated adoption of DexCom ONE in France. This implies a significant growth opportunity for the company going ahead. The latest launch is likely to help the company to sustain its strong top and bottom-line growth trend, potentially leading to higher stock price.
Industry Prospects
Per a report by Knowledge Sourcing Intelligence, the wearable CGM market in France was valued at $90.6 million in 2021 and is likely to witness a CAGR of 17.4% (till 2028) to reach $278 million. Factors like high prevalence of type I and type II diabetes, launch of improved CGM devices, government awareness programs and reimbursement coverage for CGM devices are expected to drive the market.
Given the market potential, the launch of DexCom ONE is likely to provide a boost to DexCom’s already booming CGM business.
Notable Developments
In September, DexCom announced the availability of DexCom G6 CGM system that can connect with the Omnipod 5 Automated Insulin Delivery system in Germany.
In July, DexCom announced that its next-generation DexCom G7 CGM system received Health Canada’s approval for people with all types of diabetes, aged two years and above.
The same month, DexCom announced better-than-expected second-quarter results. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Moreover, expansion of coverage for CGM systems during the quarter supported growth, which is likely to continue for the rest of 2023. The availability of new sensors like G6 and G7 in new international markets is also boosting revenue growth.
DexCom, Inc. Price
DexCom, Inc. price | DexCom, Inc. Quote
Zacks Rank & Stocks to Consider
DXCM currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Align Technology (ALGN - Free Report) , HealthEquity, Inc. (HQY - Free Report) and McKesson Corporation (MCK - Free Report) .
Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ALGN’s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company’s shares have risen 57.5% year to date compared with the industry’s 11.4% growth.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.1%.
The company’s shares have rallied 12% year to date against the industry’s 10.3% decline.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%.
The stock has rallied 12% year to date compared with the industry’s 11.4% growth.